Terms: = Breast cancer AND NSD1, FLJ44628, 64324, ENSG00000165671, Q96L73, FLJ22263, DKFZp666C163, ARA267, STO, SOTOS AND Diagnosis
5 results:
1. Treatment side affects exercising microvascular oxygenation response in active breast cancer survivors: A pilot study.
Cayot TE; Herbert B; Klika RJ
Clin Physiol Funct Imaging; 2023 Mar; 43(2):96-102. PubMed ID: 36376074
[TBL] [Abstract] [Full Text] [Related]
2. Clinical and molecular characteristics of estrogen receptor-positive ultralow risk breast cancer tumors identified by the 70-gene signature.
Johansson A; Yu NY; Iftimi A; Tobin NP; van 't Veer L; Nordenskjöld B; Benz CC; Fornander T; Perez-Tenorio G; Stål O; Esserman LJ; Yau C; Lindström LS
Int J Cancer; 2022 Jun; 150(12):2072-2082. PubMed ID: 35179782
[TBL] [Abstract] [Full Text] [Related]
3. Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative breast cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the stockholm Tamoxifen Randomized Clinical Trial.
Dar H; Johansson A; Nordenskjöld A; Iftimi A; Yau C; Perez-Tenorio G; Benz C; Nordenskjöld B; Stål O; Esserman LJ; Fornander T; Lindström LS
JAMA Netw Open; 2021 Jun; 4(6):e2114904. PubMed ID: 34190995
[TBL] [Abstract] [Full Text] [Related]
4. Tamoxifen therapy benefit for patients with 70-gene signature high and low risk.
van 't Veer LJ; Yau C; Yu NY; Benz CC; Nordenskjöld B; Fornander T; Stål O; Esserman LJ; Lindström LS
Breast Cancer Res Treat; 2017 Nov; 166(2):593-601. PubMed ID: 28776283
[TBL] [Abstract] [Full Text] [Related]
5. Use of Molecular Tools to Identify Patients With Indolent breast cancers With Ultralow Risk Over 2 Decades.
Esserman LJ; Yau C; Thompson CK; van 't Veer LJ; Borowsky AD; Hoadley KA; Tobin NP; Nordenskjöld B; Fornander T; Stål O; Benz CC; Lindström LS
JAMA Oncol; 2017 Nov; 3(11):1503-1510. PubMed ID: 28662222
[TBL] [Abstract] [Full Text] [Related]